Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Dendritic cells in cancer immunology and immunotherapy.

Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D.

Nat Rev Immunol. 2019 Aug 29. doi: 10.1038/s41577-019-0210-z. [Epub ahead of print] Review.

PMID:
31467405
2.

Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation.

Berraondo P, Ochoa MC, Olivera I, Melero I.

Cancer Discov. 2019 Aug;9(8):1003-1005. doi: 10.1158/2159-8290.CD-19-0696.

PMID:
31371324
3.

Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack.

Salas-Benito D, Melero I, Ponz-Sarvise M.

Clin Cancer Res. 2019 Sep 15;25(18):5435-5437. doi: 10.1158/1078-0432.CCR-19-1753. Epub 2019 Jul 17.

PMID:
31315885
4.

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity.

Alvarez M, Otano I, Minute L, Ochoa MC, Perez-Ruiz E, Melero I, Berraondo P.

Cell Stress. 2019 Jun 27;3(7):236-239. doi: 10.15698/cst2019.07.193.

5.

Twists and turns to translating 4-1BB cancer immunotherapy.

Sanmamed MF, Etxeberría I, Otano I, Melero I.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaax4738. doi: 10.1126/scitranslmed.aax4738. Review.

PMID:
31189719
6.

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells.

Ochoa MC, Perez-Ruiz E, Minute L, Oñate C, Perez G, Rodriguez I, Zabaleta A, Alignani D, Fernandez-Sendin M, Lopez A, Muntasell A, Sanmamed MF, Paiva B, Lopez-Botet M, Berraondo P, Melero I.

Oncoimmunology. 2019 Apr 13;8(7):1599636. doi: 10.1080/2162402X.2019.1599636. eCollection 2019.

PMID:
31143521
7.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. doi: 10.1158/1078-0432.CCR-18-4142. Epub 2019 May 3.

PMID:
31053602
8.

Immunotherapeutic effects of intratumoral nanoplexed poly I:C.

Aznar MA, Planelles L, Perez-Olivares M, Molina C, Garasa S, Etxeberría I, Perez G, Rodriguez I, Bolaños E, Lopez-Casas P, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Teijeira A, Quintero M, Melero I.

J Immunother Cancer. 2019 May 2;7(1):116. doi: 10.1186/s40425-019-0568-2.

9.

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.

Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, de Andrea C, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Llacer C, Alvarez M, de Luque V, Molina C, Teijeira A, Berraondo P, Melero I.

Nature. 2019 May;569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1.

PMID:
31043740
10.

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.

Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, Teijeira A, Kandalaft LE, Romero P, Coukos G, Neyns B, Sancho D, Melero I, de Vries IJM.

J Immunother Cancer. 2019 Apr 18;7(1):109. doi: 10.1186/s40425-019-0580-6. Review.

11.

Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.

Wculek SK, Amores-Iniesta J, Conde-Garrosa R, Khouili SC, Melero I, Sancho D.

J Immunother Cancer. 2019 Apr 8;7(1):100. doi: 10.1186/s40425-019-0565-5.

12.

Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.

Elgendy M, Fusco JP, Segura V, Lozano MD, Minucci S, Echeveste JI, Gurpide A, Andueza M, Melero I, Sanmamed MF, Ruiz MR, Calvo A, Pascual JI, Velis JM, Miñana B, Valle RD, Pio R, Agorreta J, Abengozar M, Colecchia M, Brich S, Renne SL, Guruceaga E, Patiño-García A, Perez-Gracia JL.

Int J Cancer. 2019 Oct 1;145(7):1991-2001. doi: 10.1002/ijc.32256. Epub 2019 Mar 30.

PMID:
30848481
13.

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS.

Clin Cancer Res. 2019 Aug 1;25(15):4592-4602. doi: 10.1158/1078-0432.CCR-18-1538. Epub 2019 Mar 1. Review.

PMID:
30824587
14.

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I.

Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11.

PMID:
30742120
15.

Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?

Perez-Gracia JL, Sanmamed MF, Melero I.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S356-S357. doi: 10.21037/tlcr.2018.10.12. No abstract available.

16.

TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.

Rodríguez-Ruiz ME, Rodríguez I, Mayorga L, Labiano T, Barbes B, Etxeberria I, Ponz-Sarvise M, Azpilikueta A, Bolaños E, Sanmamed MF, Berraondo P, Calvo FA, Barcelos-Hoff MH, Perez-Gracia JL, Melero I.

Mol Cancer Ther. 2019 Mar;18(3):621-631. doi: 10.1158/1535-7163.MCT-18-0558. Epub 2019 Jan 25.

PMID:
30683810
17.

Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Baraibar I, Melero I, Ponz-Sarvise M, Castanon E.

Drug Saf. 2019 Feb;42(2):281-294. doi: 10.1007/s40264-018-0774-8. Review.

PMID:
30649742
18.

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.

Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L.

Cell. 2019 Jan 10;176(1-2):334-347.e12. doi: 10.1016/j.cell.2018.11.010. Epub 2018 Dec 20.

PMID:
30580966
19.

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.

Zapata JM, Perez-Chacon G, Carr-Baena P, Martinez-Forero I, Azpilikueta A, Otano I, Melero I.

Front Immunol. 2018 Nov 15;9:2618. doi: 10.3389/fimmu.2018.02618. eCollection 2018. Review.

20.

Immunodivergence in Metastatic Colorectal Cancer.

de Andrea CE, Schalper KA, Sanmamed MF, Melero I.

Cancer Cell. 2018 Dec 10;34(6):876-878. doi: 10.1016/j.ccell.2018.11.012.

PMID:
30537510
21.

Immune mechanisms mediating abscopal effects in radioimmunotherapy.

Rodriguez-Ruiz ME, Rodriguez I, Leaman O, López-Campos F, Montero A, Conde AJ, Aristu JJ, Lara P, Calvo FM, Melero I.

Pharmacol Ther. 2019 Apr;196:195-203. doi: 10.1016/j.pharmthera.2018.12.002. Epub 2018 Dec 5. Review.

PMID:
30529041
22.

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.

Compte M, Harwood SL, Muñoz IG, Navarro R, Zonca M, Perez-Chacon G, Erce-Llamazares A, Merino N, Tapia-Galisteo A, Cuesta AM, Mikkelsen K, Caleiras E, Nuñez-Prado N, Aznar MA, Lykkemark S, Martínez-Torrecuadrada J, Melero I, Blanco FJ, Bernardino de la Serna J, Zapata JM, Sanz L, Alvarez-Vallina L.

Nat Commun. 2018 Nov 15;9(1):4809. doi: 10.1038/s41467-018-07195-w.

23.

Cytokines in clinical cancer immunotherapy.

Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I.

Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Review.

PMID:
30413827
24.

Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.

Sánchez-Paulete AR, Teijeira Á, Quetglas JI, Rodríguez-Ruiz ME, Sánchez-Arráez Á, Labiano S, Etxeberria I, Azpilikueta A, Bolaños E, Ballesteros-Briones MC, Casares N, Quezada SA, Berraondo P, Sancho D, Smerdou C, Melero I.

Cancer Res. 2018 Dec 1;78(23):6643-6654. doi: 10.1158/0008-5472.CAN-18-0933. Epub 2018 Oct 8.

PMID:
30297531
25.

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).

Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J.

Ann Oncol. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423.

26.

A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis.

Rodriguez J, Castañón E, Perez-Gracia JL, Rodriguez I, Viudez A, Alfaro C, Oñate C, Perez G, Rotellar F, Inogés S, López-Diaz de Cerio A, Resano L, Ponz-Sarvise M, Rodriguez-Ruiz ME, Chopitea A, Vera R, Melero I.

J Immunother Cancer. 2018 Sep 29;6(1):96. doi: 10.1186/s40425-018-0405-z.

27.

For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity.

Marquez-Rodas I, Aznar MA, Calles A, Melero I.

Clin Cancer Res. 2019 Feb 15;25(4):1127-1129. doi: 10.1158/1078-0432.CCR-18-2690. Epub 2018 Sep 27.

PMID:
30262506
28.

ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes.

Yanguas A, Garasa S, Teijeira Á, Aubá C, Melero I, Rouzaut A.

Front Immunol. 2018 Sep 12;9:2084. doi: 10.3389/fimmu.2018.02084. eCollection 2018.

29.

An RNA toolbox for cancer immunotherapy.

Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E, Melero I.

Nat Rev Drug Discov. 2018 Oct;17(10):751-767. doi: 10.1038/nrd.2018.132. Epub 2018 Sep 7. Review.

PMID:
30190565
30.

International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain.

Berraondo P, Aznar MA, Perez-Ruiz E, Rodriguez-Ruiz ME, Castañon E, Perez-Gracia JL, Melero I.

Cancer Immunol Immunother. 2018 Nov;67(11):1809-1813. doi: 10.1007/s00262-018-2240-y. Epub 2018 Sep 4. No abstract available.

PMID:
30182281
31.

Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.

Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S.

Trends Immunol. 2018 Aug;39(8):644-655. doi: 10.1016/j.it.2018.06.001. Epub 2018 Jul 11. Review.

32.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

33.

Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy.

Etxeberria I, Teijeira A, Montuenga LM, Berraondo P, Melero I.

Cancer Discov. 2018 Jul;8(7):794-796. doi: 10.1158/2159-8290.CD-18-0573.

34.

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.

Fusco JP, Pita G, Pajares MJ, Andueza MP, Patiño-García A, de-Torres JP, Gurpide A, Zulueta J, Alonso R, Alvarez N, Pio R, Melero I, Sanmamed MF, Rodriguez Ruiz M, Gil-Bazo I, Lopez-Picazo JM, Casanova C, Baz Davila R, Agudo A, Lozano MD, Gonzalez A, Sala N, Ardanaz E, Benitez J, Montuenga L, Gonzalez-Neira A, Perez-Gracia JL.

Cancer Med. 2018 May 15. doi: 10.1002/cam4.1500. [Epub ahead of print]

35.

Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.

Teijeira A, Labiano S, Garasa S, Etxeberria I, Santamaría E, Rouzaut A, Enamorado M, Azpilikueta A, Inoges S, Bolaños E, Aznar MA, Sánchez-Paulete AR, Sancho D, Melero I.

Cancer Immunol Res. 2018 Jul;6(7):798-811. doi: 10.1158/2326-6066.CIR-17-0767. Epub 2018 Apr 20.

36.

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.

Martinez-Calle N, Rodriguez-Otero P, Villar S, Mejías L, Melero I, Prosper F, Marinello P, Paiva B, Idoate M, San-Miguel J.

Haematologica. 2018 Jul;103(7):e318-e321. doi: 10.3324/haematol.2017.185777. Epub 2018 Apr 12. No abstract available.

37.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.

Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089.

PMID:
29554212
38.

Revisiting Interleukin-12 as a Cancer Immunotherapy Agent.

Berraondo P, Etxeberria I, Ponz-Sarvise M, Melero I.

Clin Cancer Res. 2018 Jun 15;24(12):2716-2718. doi: 10.1158/1078-0432.CCR-18-0381. Epub 2018 Mar 16.

39.

Introducing a New Series: Immunotherapy Facts and Hopes.

Melero I, Sznol M, Tessmer MS, Whiteside TL, Wolchok JD.

Clin Cancer Res. 2018 Apr 15;24(8):1773-1774. doi: 10.1158/1078-0432.CCR-18-0408. Epub 2018 Feb 23. No abstract available.

40.

Radiation effects on antitumor immune responses: current perspectives and challenges.

Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I, Lecanda F.

Ther Adv Med Oncol. 2018 Jan 18;10:1758834017742575. doi: 10.1177/1758834017742575. eCollection 2018. Review.

41.

Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.

Ochoa MC, Minute L, López A, Pérez-Ruiz E, Gomar C, Vasquez M, Inoges S, Etxeberria I, Rodriguez I, Garasa S, Mayer JA, Wirtz P, Melero I, Berraondo P.

Oncoimmunology. 2017 Nov 13;7(2):e1393597. doi: 10.1080/2162402X.2017.1393597. eCollection 2018.

42.

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

Azpilikueta A, Bolaños E, Lang V, Labiano S, Aznar MA, Etxeberria I, Teijeira A, Rodriguez-Ruiz ME, Perez-Gracia JL, Jure-Kunkel M, Zapata JM, Rodriguez MS, Melero I.

Oncoimmunology. 2017 Sep 21;7(1):e1368605. doi: 10.1080/2162402X.2017.1368605. eCollection 2017.

43.

Cancer immunotherapy full speed ahead.

Melero I, Navarro B, Teijeira A, Coukos G.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii1-xii2. doi: 10.1093/annonc/mdx739. No abstract available.

PMID:
29253117
44.

Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.

Sánchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL, Sánchez-Arráez A, Sancho D, Melero I.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii74. doi: 10.1093/annonc/mdx727. No abstract available.

PMID:
29253116
45.

Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes.

Iñarrairaegui M, Melero I, Sangro B.

Clin Cancer Res. 2018 Apr 1;24(7):1518-1524. doi: 10.1158/1078-0432.CCR-17-0289. Epub 2017 Nov 14. Review.

46.

CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes.

Aznar MA, Labiano S, Diaz-Lagares A, Molina C, Garasa S, Azpilikueta A, Etxeberria I, Sanchez-Paulete AR, Korman AJ, Esteller M, Sandoval J, Melero I.

Cancer Immunol Res. 2018 Jan;6(1):69-78. doi: 10.1158/2326-6066.CIR-17-0159. Epub 2017 Nov 13.

47.

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.

Chester C, Sanmamed MF, Wang J, Melero I.

Blood. 2018 Jan 4;131(1):49-57. doi: 10.1182/blood-2017-06-741041. Epub 2017 Nov 8. Review.

48.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K.

Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.

49.

Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.

Sánchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL, Sánchez-Arráez A, Sancho D, Melero I.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii44-xii55. doi: 10.1093/annonc/mdx237. Erratum in: Ann Oncol. 2017 Dec 1;28(suppl_12):xii74.

PMID:
28945841
50.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

Supplemental Content

Loading ...
Support Center